Abstract This Consensus Statement from an international, multidisciplinary workshop
sponsored by the Pituitary Society offers evidence-based graded consensus …

Giant prolactinomas are rare tumours, representing only 2–3% of all prolactin (PRL)-
secreting tumours and raising special diagnostic and therapeutic challenges. Based on …

Context: Familial pituitary adenomas occur rarely in the absence of multiple endocrine
neoplasia type 1 (MEN1) and Carney complex (CNC). Objective: Our objective was to …

Abstract Context and Objective: Predicting pituitary tumor behavior remains a challenge.
This multiparameter investigation aimed to identify markers for recurrence and progression …

Background Giant prolactinomas are an unusual subset of macroprolactinomas and are
more commonly found in men. The goal of this review is to propose a giant prolactinoma …

Context A sex difference in the progression of prolactin (PRL) tumors has been disputed for
years. Objective To compare tumor characteristics and postoperative clinical course …

Context Multiple endocrine neoplasia type 1 (MEN1) disease is an autosomal dominant
syndrome that is believed to equally affect men and women. This assumption has never …

Invasive pituitary adenomas and pituitary carcinomas are clinically indistinguishable until
identification of metastases. Optimal management and survival outcomes for both are not …

Background and Objective: Most patients with prolactinomas receive pharmacological
treatment only, resulting in limited research on the predictors of successful prolactinoma …

Context Prolactinomas in men are usually large and invasive, presenting with signs and
symptoms of hypogonadism and mass effects, including visual damage. Prolactin levels are …